181 related articles for article (PubMed ID: 12709044)
21. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
Björkman S
Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
23. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
Barrowcliffe TW; Raut S; Sands D; Hubbard AR
Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
[TBL] [Abstract][Full Text] [Related]
24. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
Rea C; Dunkerley A; Sørensen B; Rangarajan S
Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
[TBL] [Abstract][Full Text] [Related]
26. A blinded in vitro study with Refacto mock plasma samples: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution.
Caron C; Dautzenberg MD; Delahousse B; Droulle C; Pouzol P; Dubanchet A; Rothschild C
Haemophilia; 2002 Sep; 8(5):639-43. PubMed ID: 12199672
[TBL] [Abstract][Full Text] [Related]
27. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
Deitcher SR; Tuller J; Johnson JA
Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
[TBL] [Abstract][Full Text] [Related]
28. Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies.
Kitchen S; Tiefenbacher S; Gosselin R
Semin Thromb Hemost; 2017 Apr; 43(3):331-337. PubMed ID: 28264199
[TBL] [Abstract][Full Text] [Related]
29. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.
Hazendonk HC; van Moort I; Fijnvandraat K; Kruip MJ; Laros-van Gorkom BA; van der Meer FJ; Meijer K; Peters M; Schutgens RE; Zwaan CM; Driessens MH; Polinder S; Leebeek FW; Mathôt RA; Cnossen MH
Thromb Haemost; 2015 Aug; 114(3):639-44. PubMed ID: 26062822
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
Amiral J; Seghatchian J
Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
[TBL] [Abstract][Full Text] [Related]
31. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).
Santoro C; Iorio A; Ferrante F; Pallotta A; Pignoloni P; Biondo F; Agnelli G; Mazzucconi MG
Haemophilia; 2009 May; 15(3):779-87. PubMed ID: 19298379
[TBL] [Abstract][Full Text] [Related]
32. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement.
Van den Bossche D; Peerlinck K; Jacquemin M
Int J Lab Hematol; 2018 May; 40 Suppl 1():21-29. PubMed ID: 29741261
[TBL] [Abstract][Full Text] [Related]
33. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.
Turecek PL; Romeder-Finger S; Apostol C; Bauer A; Crocker-Buqué A; Burger DA; Schall R; Gritsch H
Haemophilia; 2016 Nov; 22(6):957-965. PubMed ID: 27353010
[TBL] [Abstract][Full Text] [Related]
34. Importance of pharmacokinetics in the management of hemophilia.
Barnes C
Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
[TBL] [Abstract][Full Text] [Related]
35. The pharmacokinetics of clotting factor therapy.
Berntorp E; Björkman S
Haemophilia; 2003 Jul; 9(4):353-9. PubMed ID: 12828668
[TBL] [Abstract][Full Text] [Related]
36. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ; Obaji SG; Collins PW
Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay.
Lee CA; Owens D; Bray G; Giangrande P; Collins P; Hay C; Gomperts E; Schroth P; Barrowcliffe T
Thromb Haemost; 1999 Dec; 82(6):1644-7. PubMed ID: 10613649
[TBL] [Abstract][Full Text] [Related]
38. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
[TBL] [Abstract][Full Text] [Related]
39. Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products.
Berntorp E; Andersson NG
Semin Thromb Hemost; 2016 Jul; 42(5):518-25. PubMed ID: 27096762
[TBL] [Abstract][Full Text] [Related]
40. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators.
Dodt J; Hubbard AR; Wicks SJ; Gray E; Neugebauer B; Charton E; Silvester G
Haemophilia; 2015 Jul; 21(4):543-9. PubMed ID: 25623631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
